Clicky

Dermata Therapeutics, Inc.(DRMA)

Description: Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. Its lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. The company was founded in 2014 and is headquartered in San Diego, California.


Keywords: Biotechnology Organ Systems Psoriasis Dermatology Skin Acne Rosacea Acne Vulgaris Cutaneous Conditions Acneiform Eruptions

Home Page: www.dermatarx.com

DRMA Technical Analysis

3525 Del Mar Heights Road
San Diego, CA 92130
United States
Phone: 858 800 2543


Officers

Name Title
Mr. Gerald T. Proehl Founder, Pres, CEO & Chairman
Mr. David F. Hale Co-Founder & Lead Independent Director
Ms. Kyri K. Van Hoose CPA, M.B.A. Sr. VP & CFO
Dr. Christopher J. Nardo M.P.H., Ph.D. Sr. VP & Chief Devel. Officer
Mr. Sean Proehl Sr. Director of Legal & Bus. Devel.
Dr. Maria Bedoya Toro Munera M.B.A., Ph.D. Sr. VP of Regulatory Affairs & Quality Assurance

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.3031
Price-to-Sales TTM: 0
IPO Date: 2021-08-13
Fiscal Year End: December
Full Time Employees: 8
Back to stocks